PT Prodia Widyahusada TbkPRWDF 69 Debt-to-EBITDA is 0.06 as of Mar. 2026, which is 14% below its 10-year median of 0.07. GuruFocus rates PRWDF with a GF Score™ of 69/100. The stock has 2 warning signs investors should review. Among 112 Medical Diagnostics & Research companies, PT Prodia Widyahusada Tbk ranks better than 95.54% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for PT Prodia Widyahusada Tbk's Debt-to-EBITDA or its related term are showing as below:
PRWDF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.04 Med: 0.07 Max: 0.65
Current: 0.04
During the past 13 years, the highest Debt-to-EBITDA Ratio of PT Prodia Widyahusada Tbk was 0.65. The lowest was 0.04. And the median was 0.07.
PRWDF's Debt-to-EBITDA is ranked better than 95.54% of 112
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.31
vs PRWDF: 0.04
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
PT Prodia Widyahusada Tbk Debt-to-EBITDA Related Terms
PT Prodia Widyahusada Tbk Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRWDF vs TMO, DHR, IDXX: Debt-to-EBITDA Comparison
For the Diagnostics & Research subindustry, PT Prodia Widyahusada Tbk's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Prodia Widyahusada Tbk Debt-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, PT Prodia Widyahusada Tbk's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PT Prodia Widyahusada Tbk's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
PT Prodia Widyahusada Tbk (PRWDF) has a Debt-to-EBITDA of 0.06 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on PT Prodia Widyahusada Tbk. This is 14% below median its historical median of 0.07. Over the past decade, PT Prodia Widyahusada Tbk's Debt-to-EBITDA has ranged from 0.04 to 0.65. According to the industry distribution chart, PT Prodia Widyahusada Tbk ranks #5 out of 112 companies in the Medical Diagnostics & Research industry, placing it in the top 4.5%.
Is PT Prodia Widyahusada Tbk's Debt-to-EBITDA too high?
PT Prodia Widyahusada Tbk's current Debt-to-EBITDA of 0.06 is 14% below median its 10-year median of 0.07. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 0.65. The Medical Diagnostics & Research industry median Debt-to-EBITDA is 2.31. PT Prodia Widyahusada Tbk's value of 0.06 is 97.4% below this industry median. Based on the distribution chart, PT Prodia Widyahusada Tbk ranks #5 out of 112 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, PT Prodia Widyahusada Tbk has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does PT Prodia Widyahusada Tbk's Debt-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, PT Prodia Widyahusada Tbk ranks #5 out of 112 companies for Debt-to-EBITDA. This places PT Prodia Widyahusada Tbk in the top 5% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 2.31. PT Prodia Widyahusada Tbk's value of 0.06 is 97.4% below this benchmark. Historically, PT Prodia Widyahusada Tbk's own Debt-to-EBITDA has ranged from 0.04 to 0.65 over the past decade. While the company's 10-year median is 0.07 vs. the industry median of 2.31, PT Prodia Widyahusada Tbk has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.31, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Prodia Widyahusada Tbk's current Debt-to-EBITDA of 0.06 is 97.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on PT Prodia Widyahusada Tbk. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Prodia Widyahusada Tbk's current Debt-to-EBITDA is 0.06, which is 14% below median its own 10-year median of 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Prodia Widyahusada Tbk stock overvalued right now?
PT Prodia Widyahusada Tbk (PRWDF) has a current Debt-to-EBITDA of 0.06. The current Debt-to-EBITDA is 0.06, which is 14% below median its 10-year median of 0.07 and 97.4% below the Medical Diagnostics & Research industry median of 2.31. PT Prodia Widyahusada Tbk's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For PT Prodia Widyahusada Tbk (PRWDF), the current Debt-to-EBITDA is 0.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PT Prodia Widyahusada Tbk provides health care testing services. The company provides analytic and diagnostic services for the medical professionals. It is engaged in health laboratories by conducting business activities such as setting up clinics, health laboratories, management of hospitals, and health checkup services. Its operating segments are Central: Jakarta; Sumatera: Sumatera, Kepulauan Riau; Greater Jakarta: Jakarta, Bogor, Depok, Tangerang, Bekasi, Lampung, Pangkal Pinang; West Java; Central Java; East Java, Bali, Nusa Tenggara; Kalimantan Sulampua: Kalimantan, Sulawesi, Ambon, Papua.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRWDF has been successfully added to your 